Organogenesis Holdings Inc.
NASDAQ:ORGODrug Manufacturers - Specialty & Generic
+$0.08 today
- Market cap
- $110.75M
- Beta
- 1.33
- P/E (TTM)
- -1086.7
- EPS (TTM)
- -$0.00
Volume 0.86M
Average 1.49M
ORGO EBITDA Margin
EBITDA as a percentage of revenue.
Organogenesis Holdings Inc.NASDAQ: ORGO
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -150.7%
EBITDA Margin was -150.7% in Q1 FY2026, down 128.2 pp from a year earlier. On a trailing-twelve-month basis it was 7.3%, up 8.1 pp year over year. Over 3 fiscal years it widened by 4.2 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 2 analysts of -86.1% for the fiscal year ending Dec 2026, down from 13.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -150.7%-182.0 pp QoQ
- Last fiscal yearDec 2025
- 13.1%+9.9 pp YoY
- LTMMar 2026
- 7.3%+8.1 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -128.2 pp | -65.9 pp | +62.3 pp |
| 1 year | +9.9 pp | -99.2 pp | -109.0 pp |
| 3 years | +4.2 pp | -28.2 pp | -32.3 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 13.1%
- Year-over-year change
- +9.9pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.1% | +9.9pp |
| FY2024 | 2024-12-31 | 3.3% | -5.0pp |
| FY2023 | 2023-12-31 | 8.3% | -0.6pp |
| FY2022 | 2022-12-31 | 8.9% | -9.7pp |
| FY2021 | 2021-12-31 | 18.6% | — |
EBITDA Margin vs competitors
How ORGO compares with its peers on the latest reported figures
- ORGO's LTM Mar 2026 EBITDA Margin of 7.3% is the 4th highest of the 9 companies compared; the peer median is 2.3%.
- Its year-over-year change of +8.1 pp is the 5th highest of 9, against a peer median of +8.3 pp.
- Over three fiscal years its change of +4.2 pp compares with a peer median of +29.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 29.3% | -22.9 pp | -7.6 pp | |
| LTM Mar 2026 | 22.8% | +10.3 pp | +31.0 pp | |
| LTM Mar 2026 | 9.5% | +43.6 pp | +249.5 pp | |
| LTM Mar 2026 | 7.3% | +8.1 pp | +4.2 pp | |
| LTM Mar 2026 | 5.3% | +10.5 pp | +50.9 pp | |
| LTM Apr 2026 | -0.7% | -9.9 pp | -12.9 pp | |
| LTM Feb 2026 | -1.7% | -1.9 pp | -2.9 pp | |
| LTM Mar 2026 | -4.6% | +6.2 pp | +28.7 pp | |
| LTM Mar 2026 | -333.1% | +482.9 pp | +448.9 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ORGO) | 2.3% | +8.3 pp | +29.8 pp | |
Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 467.36M | 450.89M | 433.14M | 482.04M | 563.03M |
| Cost of Revenue | 114.2M | 105.02M | 106.48M | 115.74M | 137.52M |
| Gross Profit | 353.16M | 345.87M | 326.66M | 366.3M | 425.51M |
| Gross Margin | 75.6% | 76.7% | 75.4% | 76.0% | 75.6% |
| Research & Development | 30.74M | 39.76M | 44.38M | 50.27M | 44.54M |
| Selling, General & Admin | 250.2M | 283.81M | 269.75M | 294.51M | 326.24M |
| Operating Expenses | 280.94M | 323.57M | 314.13M | 367.59M | 369.64M |
| Depreciation & Amortization | 16.68M | 18.03M | 23.45M | 17.03M | 26.94M |
| EBITDA | 87M | 40.32M | 36.03M | 15.76M | 73.91M |
| EBITDA Margin | 18.6% | 8.9% | 8.3% | 3.3% | 13.1% |
| Operating Income | 72.22M | 22.3M | 12.53M | (1.28M) | 55.87M |
| Operating Margin | 15.5% | 4.9% | 2.9% | -0.3% | 9.9% |
| Interest Income | 0 | 0 | 0 | 0 | 2.28M |
| Interest Expense | 7.24M | 2.01M | 2.19M | 1.54M | 0 |
| Other Income / Expenses | (9.13M) | (2.02M) | (2.13M) | (1.52M) | (8.9M) |
| Income Before Tax | 63.09M | 20.28M | 10.39M | (2.81M) | 46.97M |
| Pre-Tax Margin | 13.5% | 4.5% | 2.4% | -0.6% | 8.3% |
| Income Tax Expense | (31.12M) | 4.75M | 5.45M | (3.67M) | 9.94M |
| Net Income | 94.2M | 15.53M | 4.95M | 861K | 37.03M |
| Net Margin | 20.2% | 3.4% | 1.1% | 0.2% | 6.6% |
| EPS (Basic) | 0.73 | 0.12 | 0.04 | (0.01) | 0.16 |
| EPS (Diluted) | 0.70 | 0.12 | 0.04 | (0.01) | 0.15 |
| Weighted Avg Shares | 128.33M | 130.07M | 131.23M | 131.67M | 126.74M |
| Weighted Avg Shares (Diluted) | 133.66M | 132.38M | 132.75M | 131.67M | 130.25M |
Organogenesis Holdings Inc.
NASDAQ:ORGO
Intrinsic Alpha fair value
Locked
Current Price
$0.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.